Review

Nutrition in autism spectrum disorders: A review of evidences for an emerging central role in aetiology, expression, and management

  • Autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders whose aetiology remains largely unknown, but for which environmental factors appear to be important. Emerging evidences suggest that nutrition may play a major role in the aetiology of ASD; also, specific maternal nutritional-deficiencies appear to be associated with an increased risk in offsprings. In addition, studies are beginning to reveal the beneficial effects of dietary supplementation or restriction in the management of ASD; while at the same time debunking the myths that surround certain purportedly-therapeutic dietary manipulations. In this narrative review (using information from internet databases such as Google scholar, PubMed, Scopus and authoritative texts), we examine the emerging central role of nutrition in relation to aetiology, symptomatology, management, and indices of outcome in ASD; by highlighting available scientific evidences pertaining to the impacts of different dietary manipulations and nutritional supplementation. We also consider the likely future roles of nutrition in ASD, as science continues to grapple with the understanding of a group of neurodevelopmental disorders that are emerging to be largely “nutritional illnesses”.

    Citation: Olakunle James Onaolapo, Adejoke Yetunde Onaolapo. Nutrition in autism spectrum disorders: A review of evidences for an emerging central role in aetiology, expression, and management[J]. AIMS Medical Science, 2018, 5(2): 122-144. doi: 10.3934/medsci.2018.2.122

    Related Papers:

    [1] Ivana Sirangelo, Margherita Borriello, Gaetano Irace, Clara Iannuzzi . Intrinsic blue-green fluorescence in amyloyd fibrils. AIMS Biophysics, 2018, 5(2): 155-165. doi: 10.3934/biophy.2018.2.155
    [2] Alessandro Didonna, Federico Benetti . Post-translational modifications in neurodegeneration. AIMS Biophysics, 2016, 3(1): 27-49. doi: 10.3934/biophy.2016.1.27
    [3] Nick K. Olrichs, J. Bernd Helms . Novel insights into the function of the conserved domain of the CAP superfamily of proteins. AIMS Biophysics, 2016, 3(2): 232-246. doi: 10.3934/biophy.2016.2.232
    [4] Jany Dandurand, Angela Ostuni, Maria Francesca Armentano, Maria Antonietta Crudele, Vincenza Dolce, Federica Marra, Valérie Samouillan, Faustino Bisaccia . Calorimetry and FTIR reveal the ability of URG7 protein to modify the aggregation state of both cell lysate and amylogenic α-synuclein. AIMS Biophysics, 2020, 7(3): 189-203. doi: 10.3934/biophy.2020015
    [5] Nicola Gaetano Gatta, Gaetano Cammarota, Vittorio Gentile . Possible roles of transglutaminases in molecular mechanisms responsible for human neurodegenerative diseases. AIMS Biophysics, 2016, 3(4): 529-545. doi: 10.3934/biophy.2016.4.529
    [6] J. Dandurand, E. Dantras, C. Lacabanne, A. Pepe, B. Bochicchio, V. Samouillan . Thermal and dielectric fingerprints of self-assembling elastin peptides derived from exon30. AIMS Biophysics, 2021, 8(3): 236-247. doi: 10.3934/biophy.2021018
    [7] Daniela Meleleo, Cesare Sblano . Influence of cholesterol on human calcitonin channel formation. Possible role of sterol as molecular chaperone. AIMS Biophysics, 2019, 6(1): 23-38. doi: 10.3934/biophy.2019.1.23
    [8] Marek K. Korzeniowski, Barbara Baird, David Holowka . STIM1 activation is regulated by a 14 amino acid sequence adjacent to the CRAC activation domain. AIMS Biophysics, 2016, 3(1): 99-118. doi: 10.3934/biophy.2016.1.99
    [9] Nicole Shamitko-Klingensmith, Jonathan W. Boyd, Justin Legleiter . Microtubule modification influences cellular response to amyloid-β exposure. AIMS Biophysics, 2016, 3(2): 261-285. doi: 10.3934/biophy.2016.2.261
    [10] Giovanni Colonna . Protein biophysics: current limitations and prospects. AIMS Biophysics, 2025, 12(3): 333-374. doi: 10.3934/biophy.2025018
  • Autism spectrum disorders (ASDs) are a group of neurodevelopmental disorders whose aetiology remains largely unknown, but for which environmental factors appear to be important. Emerging evidences suggest that nutrition may play a major role in the aetiology of ASD; also, specific maternal nutritional-deficiencies appear to be associated with an increased risk in offsprings. In addition, studies are beginning to reveal the beneficial effects of dietary supplementation or restriction in the management of ASD; while at the same time debunking the myths that surround certain purportedly-therapeutic dietary manipulations. In this narrative review (using information from internet databases such as Google scholar, PubMed, Scopus and authoritative texts), we examine the emerging central role of nutrition in relation to aetiology, symptomatology, management, and indices of outcome in ASD; by highlighting available scientific evidences pertaining to the impacts of different dietary manipulations and nutritional supplementation. We also consider the likely future roles of nutrition in ASD, as science continues to grapple with the understanding of a group of neurodevelopmental disorders that are emerging to be largely “nutritional illnesses”.


    Alzheimer's disease (AD) is a fatal neurodegenerative disorder that is the most prevalent form of dementia. The neuropathological and neurochemical hallmarks of AD include: Synaptic loss and selective neuronal cell death; decreases in markers for certain neurotransmitters; and abnormalities in neurons and their processes as well as in the extracellular space. Two of the main features associated with AD are neurofibrillary tangles comprised of the protein tau and cerebrovascular, diffuse, and neuritic plaques composed predominantly of the amyloidogenic peptide amyloid-β (Aβ). These proteinaceous deposits of tau and Aβ consist of stable amyloid fibrils, which are β-sheet rich fibrous protein agammaegates. Similar deposition of amyloid is associated with numerous other diseases [1].

    In the early 90's, the amyloid cascade hypothesis was introduced, which postulated that Aβ agammaegation and deposition directly lead to neuronal death, resulting in AD [2]. Yet, the correlation between plaques and cognitive dysfunction in AD has been questionable for years [3][7], and with Aβ-directed therapeutic strategies failing in numerous clinical trials, the role of Aβ in AD progression is being re-evaluated [8][11]. This has led to an enhanced research focus on diffuse, soluble agammaegates of Aβ. Various small, globular agammaegates of Aβ, referred to broadly as Aβ oligomers (AβO), were detected in AD patients a few decades ago [12][14], and these AβO were originally classified as being intermediates toward the formation of amyloid fibrils. Over the years, increasing evidence points toward AβOs playing a central role in AD, as AβOs correlate more strongly with AD progression in patients and animal models [15][19]. For example, AβO formation and buildup occurs early compared with plaque buildup (much earlier than plaque deposition) in the AD brain [20][22]and CSF [23], which has led to extensive efforts to develop assays to detect AβOs for potential application as biomarkers [24][31].

    An extensive body of evidence has linked high levels of AβOs in the brain to a variety of pathogenic consequences associated with AD (summarized in Table 1). As such, there has been significant effort made to characterize AβO formation, structure, and biochemical/biophysical characteristics (such as interactions with other proteins and lipids) in the hope that underlying modes of AβO-related toxicity could be revealed [32][37]. As AβOs are metastable, highly heterogeneous in nature, and can form via a variety of different pathways, this remains a challenging task, yet progress has been made. Here, we review AβOs with a focus on biophysical characterization of their formation and structure.

    Table 1.  Toxic mechanisms associated with AβOs.
    Toxic effects of AβOs Model system(s) References
    Reduction in neural plasticity mice, rat [37][40]
    Stimulation of tau phosphorylation cortical neurons (rat), hippocampal neurons, neuroblastoma, primary neurons, Tg-Mice [41][45]
    Choline acetyltransferase Inhibition cholinergic cell lines [46],[47]
    Oxidative stress cortical neurons, hippocampal neurons, in vitro, neuroblastoma [48][51]
    Endoplasmic reticulum stress cortical astrocytes, cortical neurons (rat), fibroblasts, Tg-mice [43],[52],[53]
    Receptor disturbance cortical neurons, hippocampal neurons [54][57]
    Insulin resistance cortical neurons, hippocampal neurons, rat [40],[42],[57],[58]
    Synapse deterioration hippocampal neurons, pyramidal neurons (rat), Tg-mice [21],[35],[54],[59]
    Axonal transport cortical neurons, hippocampal, in vitro, Tg-mice [60][62]
    Astrocytes/microglia effects cortical astrocytes, Tg-mice [44],[52],[63],[64]
    Cell cycle disruption cortical neurons, Tg-mice [65],[66]
    Selective neuron death Mice [38],[67]
    Inhibition of long-term potentiation Mice [37],[40]
    Calcium dysregulation cortical neurons (rat), hippocampal neurons, primary neurons [43],[45],[48],[52]
    Modulation of metal toxicity neuroblastoma [49]
    Cytoskeleton disruption primary neurons [50]
    Modulation of Receptor/Channel Activity hippocampal neurons [48]

     | Show Table
    DownLoad: CSV

    Aβ is an approximately 4 kDA peptide (typically 40–42 amino acids long) that is derived from the transmembrane portion of the amyloid precursor protein (APP; Figure 1). The production of Aβ is achieved by the sequential cleavage of APP by two membrane-bound endoprotease activities, β- and γ-secretase. The two predominant Aβ peptides produced are 40 and 42 amino acids in length, and these peptides are referred to as Aβ40 and Aβ42 respectively. Aβ is amphipathic in nature (having a predominately hydrophilic N-terminus and a predominately hydrophobic C-terminus), which is thought to drive its agammaegation. As the C-terminal end of Aβ coincides with the transmembrane portion of APP, Aβ42 has a larger hydrophobic domain, making it more fibrillogenic compared to Aβ40 and deposits to a much greater extent in the brain [68][70]. Only about 10% of APP is processed via this Aβ producing pathway. Most APP is cleaved by the α-secretase, generating a series of much more benign peptide fragments.

    The hydrophilic N-terminal region of Aβ can adopt both an α-helical or β-sheet structure dependent on solution conditions, for example pH [71],[72]. The hydrophobic C-terminal end of Aβ has a propensity to adopt β-sheet structure upon agammaegation independent of solvent conditions [71],[72]. Beyond its amphipathic nature, several other domains have been identified in Aβ. The different polyomorphic fibril structures of Aβ are comprised of bundled β-sheets with backbones orthogonal to the fiber axis creating a cross-β structure [73], and two β-strand forming domains (residues 11–21 and 29–39 respectively) that are separated by a turn/bend region (around residues 23–26) identified through various experimental and computational studies [74][77]. The central region of Aβ (residues 16–21), contained within one of the β-strands, has enhanced amyloidogenic properties and represents a hydrophobic core [78].

    Figure 1.  APP processing and subsequent Aβ amino acid sequence with specific domains of interest specified. Proteolytic cleavage of APP is initiated at residue 671 by β-secretase followed by either non-amyloidogenic processing, cleavage at residue 687 by α-secretase, or amyloidogenic processing, cleavage at residue 711, 713, 714, or 726 by γ- secretase. The amino acid sequence below highlights the region of APP from which Aβ is produced with the numbering referring the residues in Aβ. The orange highlighted region represents the intact Aβ42 sequence. Hydropathy indexes of individual residues are color coded according to hydrophobic (blue), slightly hydrophobic (light green), and hydrophilic (red). Regions of interest and cites of secretase activity within the APP and Aβ are indicated.

    The agammaegation of Aβ (and other amyloid-forming proteins) is typically characterized in terms of fibril formation (Figure 2). Aβ fibril formation occurs via a complex agammaegation pathway. Fundamentally, AβOs can be subdivided into species that are intermediates in fibrils formation (referred to as being on pathway) or species that do not directly lead to fibrils (referred to as being off pathway). This is a contributing factor to the immense heterogeneity observed in AβO populations as will be discussed in more detail later. In general, amyloid formation proceeds via a nucleation dependent polymerization mechanism [79][81]. With this mechanism, agammaegation initially occurs via a slow nucleation phase (often called the lag phase) that involves the formation of a thermodynamically unfavorable critical nucleus that is associated with a transition from a native to non-native protein conformation. For Aβ, the critical nucleus is likely a multimeric species [82][84]. Once the critical nucleus has formed, an elongation or growth phase (characterized by a relatively rapid extension of fibril agammaegates) occurs. While numerical models can extract important parameters (lag phase times, elongation rates, critical nucleus size) from experimental data [85], the actual agammaegation pathway toward fibrils can be complicated. For example, other on pathway intermediates, like protofibrils, are also observed in Aβ agammaegation. Protofibrils are amyloid-like, elongated agammaegates with filament-like morphologies and are late-stage intermediate precursors on the agammaegation pathway to fibrils. A key aspect that facilitates on and off pathway agammaegation routes and complicates investigations of AβOs is that they possess structural plasticity and are metastable and transient in nature.

    Figure 2.  Production and aggregation Aβ. Aβ is a cleavage product of APP, a transmembrane protein. Monomeric Aβ transitions between ordered and disordered states. Once dimerization occurs, subsequent aggregation occurs either on pathway or off pathway with respect to fibril formation. The aggregates associated with these different pathways increase in molecular weight from the left to the right of the schematic. Fibrillization can proceed via several potential pathways that can populate various intermediate aggregate states, including oligomers and protofibrils. Off-pathway oligomers of various size may also form. Annular aggregates of Aβ can also form and are thought to potentially be associated with forming pore-like structures.

    Further complicating the issue is the observation that Aβ can agammaegate into a variety of morphologically distinct fibril structures, referred to as polymorphs [86][90]. This phenomenon is predicated on subtle changes of environmental conditions associated with agammaegation, and as a result, preparatory protocols employed in experiments determines the resulting Aβ fibril morphology [87]. While polymorphic agammaegates are readily observed with in vitro studies using synthetic Aβ, polymorphic structures have been observed in amyloids derived from tissue, and it is thought that variations in Aβ agammaegate morphologies may play an important role in AD [91],[92]. For example, polymorphic agammaegates and fibrils may result in distinct biological activities and levels of toxicity that could underlie variations in AD [76], and distinct fibril structures can be directly associated with individual AD patients and clinical phenotype [93],[94].

    A complicating factor in evaluating and comparing studies aimed at elucidating AβO formation, structure, and physiological impact is divergent experimental conditions, such as Aβ preparation protocols, heavily influences experimental outcomes. In terms of oligomers, the emergence of distinct fibril structure strongly suggests that there would also be distinct oligomeric precursors associated with their formation. Indeed, distinct AβO species can be observed within in vitro agammaegation assays under conditions that result in fibril polymorphs [95] (Figure 3). For studies conducted with synthetic peptide, there are a variety of protocols used to solubilize Aβ (Table 2). Typically, these protocols consist of a disagammaegation step and a reconstitution step. The disagammaegation steps usually involves the use of hydrogen bond disrupting solvents, i.e., hexafluoroisopropanol (HFIP) or trifluoroacetic acid (TFA), that break down pre-existing agammaegates within lyophilized stocks of Aβ. These solvents are often removed under vacuum, leaving a peptide film. The reconstitution step involves dissolving these peptide films into a solvent that facilitates dilution into an appropriate buffer. Dimethyl sulfoxide (DMSO) is often used, creating a concentrated stock that is diluted into the desired buffer. Disagammaegation and reconstitution can also be facilitated by changes in pH. Sometimes reconstitution is performed directly into the final buffer. Importantly, variations in preparatory protocols indeed result in different populations of oligomers (Table 2 and Figure 3), and these variations can complicate direct comparisons between different reports within the literature. Further complicating the issue, there are often distinctions observed between studies performed with synthetic Aβ and naturally derived Aβ [96]. In many studies aimed at elucidating activity of AβOs, specific preparations are used to obtain a particular population of oligomer species. These are then directly applied to different model systems, ranging from cell culture to animal models. However, there is often a lack of effort to verify that once added to the model system (which can often be a pronounced change in chemical environment) that these AβO species do not dissociate or agammaegate into a different AβO or Aβ agammaegate. To truly relate specific AβOs to a neurotoxic activity, effort should be invoked to attempt additional controls of this type.

    Table 2.  Representative disaggregation, reconstitution, and miscellaneous protocols for the preparation of Aβ and observed AβOs.
    Classification Disaggregation Reconstitution Miscellaneous Result References
    ADDLs None F12 Media 4 °C Centrifuged 14,000 ×g for 10 mins 5–6 nm by AFM (height) [38]
    ADDLs HFIP DMSO at 5 mM Aβ Sonicate 5 mins, dilute with DMEM/F12 Media A11+ [97]
    Globulomers HFIP DMSO at 5 mM Aβ Sonicate 10 mins, dilute PBS + 0.05% SDS 16–56 kDa by SDS-PAGE [98]
    Globulomers HFIP DMSO at 5 mM Aβ Dilute PBS + 0.05% SDS, Dialyze 38–48 kDa by SDS-PAGE [99]
    Aβ*56 HFIP DMSO at 5 mM Aβ Sonicate 20 min, PBS + 0.2% SDS incubate 6 h, dilute and incubated 18 h; centrifuge 3000 ×g, dialysis 56 kDa by Native-PAGE [100]
    AβOs HFIP DMSO F12 Media incubated at 4 °C for 24 h 1–4 nm by AFM [101],[102]
    AβOs HFIP/NH4OH 10 mM Tris-HCl Addition of Zn2+ 10–12 nm by AFM [97]
    AβOs TFA/HFIP (2Xs) 2 mM NaOH PBS Centrifuge 386,000 ×g 2.5 nm by AFM [87],[95]
    AβOs TFA salt/2 mM NaOH, pH ∼10.5, 1 min sonication HH PBS - 3–12 nm by AFM [103]
    AβOs 10% NH4OH (w/v) sonicated 5 mins, lyophilized 60 mM NaOH - 1–10 nm by DLS [104]
    AβOs LMW - DMSO Sonicate 1 min, centrifuge 16,000 ×g, SEC, PBS, PICUP crosslinking 4–26 kDa by SDS-PAGE [105]

     | Show Table
    DownLoad: CSV
    Figure 3.  Heterogeneity of AβOs. A series of atomic force microscopy images and size analysis, i.e. height histograms, of AβOs formed from synthetic Aβ that had been prepared by some of the protocols described in Table 2. The AβOs were prepared in the following way: (A) protocol provided in the AggreSure β-amyloid kits available from AnaSpec which consists of a reconstitution step directly into Tris buffer with bath sonication; (B) 10% NH4OH disaggregation buffer, followed by additional treatment with HFIP, and reconstitution in 2 mM NaOH (pH > 11) with subsequent dilution into Tris buffer; (C) 10% NH4OH disaggregation buffer, and reconstitution in 60 mM NaOH (pH > 11) with subsequent dilution into HEPES buffer; (D) HFIP disaggregation, reconstitution in DMSO, followed by dilution into PBS; (E) TFA disaggregation with sonication, an additional HFIP disaggregation step, reconstitution with NaOH, and dilution into PBS; (F) No disaggregation step and direct reconstitution in to phosphate buffer.

    Enormous efforts have been extended in identifying the most toxic/disease-relevant AβO species and the relevant underlying structure [9],[106],[107]. This is a daunting endeavor due to the transient nature and extensive heterogeneity associated with AβOs [108][110]. It is possible that different AβO species may activate different deleterious changes associated with AD [9],[106],[107]; however, there may also be relatively benign AβO species or even experimental artifacts [96],[108],[111]. Unraveling the physiological activity of AβOs may require separate analysis of these different species, which may be altered by preparatory protocols. The ability of smaller AβO (like dimers and trimers) to further agammaegate into large, more stable synaptotoxic assemblies [107] must be accounted for in assessing the toxic effects of specific AβO species. That is, upon the addition of preparations of AβO to cell culture or other models, AβOs may further assemble into other higher order species that may influence the associated toxic effects. Despite the inherent complexity of this endeavor, progress has been made. Aβ trimers have been linked to playing a role in inducing pathological conformational changes in tau [112]. However, crosslinked Aβ dimers were shown not to be toxic themselves, but rather contributed to toxicity by further assembling into larger assemblies [113]. A 56 kDa SDS-stable Aβ0 (referred to as Aβ*56) has been identified as a prominent specie in the AD brain [16], CSF [22], and in transgenic mouse models of AD [32],[114]. In terms of an actual biological activity, Aβ*56 interacts with N-methyl-D-aspartate receptors (NMDARs), increasing NMDAR-dependent Ca2+ influx and activation of Ca2+/calmodulin-dependent kinase IIα (CAMKIIα) [115]. Activation of CAMKIIα correlates with enhanced site-specific phosphorylation and mis-sorting of tau [115]. Smaller AβOs, namely dimers and trimers, do not appear to elicit these specific effects.

    There appears to be some common themes emerging with respect to toxicity. Toxic AβOs appear to react with oligomer specific antibodies like A11 (generic for amyloid oligomers in general, [116]) and NU4 (specific for AβOs) [117]; whereas, nontoxic AβOs demonstrate reactivity with anti-fibril antibodies like OC [116]. Importantly, toxic AβOs appear to be unrelated to plaques [116],[118]. AβOs related to amyloid plaques temporally, spatially, and structurally are nontoxic [118]. A number of toxic AβO species are larger than 50 kDa [21],[54],[118], like the previously mentioned Aβ*56 [32]. Smaller AβOs appear to be less toxic or even benign [21],[54],[118],[119], except for their ability to further agammaegated into larger assemblies. This has led to distinguishing between high molecular weight (HMW) and low molecular weight (LMW) oligomers [120]. Agammaegation mechanisms differentiating between the eventual formation of HMW and LMW AβOs already appear to deviate at the dimer stage [121]. Furthermore, LMW and HMW Aβ oligomers differentially impact synapses and memory [122],[123]; although, LMW AβOs are not always associated with memory dysfunction [116],[117]. HMW AβOs are the predominant Aβ species in the native soluble protein fraction of AD brains [124]. These HMW species in the AD brain sometimes appear to be constructed from smaller ∼7 kDa Aβ species [125]. Neurohistopathological and biochemical analyses of AβOs in the temporal cortex of AD brains implicated an Aβ dodecamer (∼55 kDa) [126]. HMW AβOs bind cultured synapses [21],[54],[118], induce reactive oxygen species (ROS) production [123], and disrupt memory function [116],[117]. With respect to the previously defined agammaegation pathways, LMW AβOs are typically on pathway to fibril formation; HMW AβOs are off-pathway [127],[128]. This is consistent with HMW AβOs being potent, as off pathway AβOs appear more toxic [129]. Collectively, these observations point to the complex interplay between different AβO species and their specific activity with respect to neurotoxicity.

    Table 3.  Methods used for analyzing AβOs.
    Technique Features of AβOs Obtained
    Atomic Force Microscopy (AFM) Morphology, population distributions
    Electron Microscopy (EM) Morphology, population distributions
    Ion-Mobility Mass Spectroscopy (IM-MS) Secondary structure, multimeric configurations
    Nuclear Magnetic Resonance 2D (NMR) Secondary structure, multimeric configurations, atomic resolution structure
    Electron Paramagnetic Resonance (EPR) Secondary structure, multimeric configurations, atomic resolution structure
    Powder X-ray Diffraction (PXRD) Atomic resolution structure
    Small Angle X-ray Scattering (SAXS) Atomic resolution structure
    Single Crystal X-ray Diffraction (SCXD) Atomic resolution structure
    SDS-Page Size distribution of multimers

     | Show Table
    DownLoad: CSV

    To facilitate structure/activity analysis, significant efforts have been made to obtain structural details of AβOs using a variety of methods (Table 3). This is required to fully elucidate the modes of interaction of AβOs with other biomolecules and related toxic mechanisms [32],[33],[35][37],[130]. Structural characterization of specific AβOs is challenging due to their transient nature and heterogeneity. AβOs can exhibit conformational plasticity that can be heavily influenced by environmental factors, further complicating such analysis. Despite these inherent challenges, efforts have been made to separate, isolate, and characterize distinct AβO species obtained from synthetic Aβ or from AD brain tissue and cell cultures [18],[32],[35][37],[114],[129],[131][136]. With regard to HMW and LMW AβOs, they are separable in vitro by size exclusion chromatography [137] or ultrafiltration with a 50 kDa molecular weight cutoff [21],[54],[118]. Quick characterization of AβOs can be accomplished by chromatographic techniques, SDS PAGE, and by the use of a variety of oligomer specific antibodies (Table 4).

    Table 4.  Anti-AβO specific antibodies.
    Antibody Epitope References
    A11 Soluble amyloid oligomers [17],[138]
    NAB61 Dimeric, oligomeric, higher order aggregates [139]
    NU-1 ADDLs specific [140]
    NU-2 ADDLs weak binding; no Aβ monomer staining [140]
    NU-4 ADDL trimer, tetramer, and 12–24 mer specific [140]

     | Show Table
    DownLoad: CSV

    One strategy that has been used to overcome obstacles associated with characterizing AβOs has been to stabilize oligomers via cross-linking. Such methods can lead to not only structural but also functional characterization of AβOs. Photo-induced crosslinking (PICUP) was initially used to stabilize and characterize LMW AβOs of Aβ40 and Aβ42 [33],[141][143].While Aβ40 primarily formed an equilibrium of dimers, trimers, and tetramers, Aβ42 agammaegated into pentamers/hexamers that further assembled into protofibrils [143]. Using mutated Aβ42 (F10, Y42), AβOs ranging from dimer to dodecamers were stabilized using PICUP [141], opening up the ability to perform structure/activity analysis on AβOs up to 50 kDa in size. AβOs can also be stabilized using dityrosine crosslinking, which occurs under elevated copper concentrations and oxidative stress [144]. Both of these conditions have been linked to AD, suggesting that the crosslinking associated with this method may be more physiologically relevant [145],[146]. In fact, dityrosine crosslinked proteins are observed in amyloid plaques and CSF from AD patients [145]. Dityrosine linkages are associated with copper-mediated stabilization of AβOs [147]. Copper stabilization is effective enough to allow for 3D structural characterization of AβOs by small-angle x-ray scattering [148], and the copper to Aβ ratio could push agammaegation toward ellipsoidal oligomers of 38 peptides (excess copper) or fibrils (excess Aβ) [119].

    Another method to overcome the metastability of Aβ species and control the agammaegation process is to complex/fuse Aβ sequences within other protein. Aβ sequences are often based on previously identified regions of the peptide that have been identified as playing a role in Aβ agammaegation (Figure 1). Such a strategy has been successful in studying monomeric structure of Aβ sequences [149]. With careful design, this method has been applied to stabilizing oligomers derived from Aβ fragments for structural characterization. Fusion of Aβ18–41 with the CDR3 loop region of a shark Ig new antigen receptor single variable domain antibody resulted in the formation and stabilization of tightly associated Aβ dimers, which could pair to form tetramers [150]. This dimer had a compact structure rather than a β-turn/β-sheet structure. Several engineered peptide macrocycles that incorporate Aβ sequences (Aβ15–23 and Aβ17–36) have been designed to contain agammaegation to the oligomeric state, and these systems have been structurally characterized by X-ray crystallography and NMR spectroscopy [151][153]. Collectively, this macrocycle strategy has revealed numerous dimers, trimers, tetramers, and higher order oligomer species that display a variety of β-sheet based structural heterogeneity.

    Due to the complex nature of Aβ agammaegation, techniques that allow for distinguishing and characterizing distinct morphological features of AβOs within heterogeneous agammaegation reactions are of enormous benefit. Both atomic force microscopy (AFM) and electron microscopy (EM) provide this capability. In particular, AFM has emerged as a particularly useful technique in studying AβO formation and morphology [95],[101],[134],[135],[154][160]. As AFM can be operated in solution, it has the ability to observe and track the behavior of individual AβOs on surfaces under physiological buffer conditions [158],[160]. The surfaces used in AFM experiments have become progressively more biologically relevant and include lipid membranes [135],[161][164]. With regard to Aβ agammaegation on lipid membranes, in solution AFM studies have demonstrated the formation of distinct oligomeric agammaegates associated with point mutation in Aβ [165], the formation of pore-like AβO morphologies [154][156], that preparation history influences AβO formation on bilayers [95], and that mechanical changes occur in bilayers associated with the presence of AβOs [166]. AFM based force spectroscopy has even been used to understand the energetics of AβO formation and stability [167],[168].

    With the recent development of high-speed AFM in solution, insights into the dynamics and fate of individual AβOs has been achieved [128],[169]. Using high-speed AFM to track the dynamics of PICUP-stabilized LMW AβOs demonstrated that these AβOs were highly dynamic in structure, fluctuating between single and multi-globular assemblies [169]. Direct visualization of Aβ agammaegation with high-speed AFM imaging demonstrates that LMW AβOs much more quickly transition to form fibrils with distinct morphologies compared with HMW AβOs [128]. Despite being classified as being off-pathway, HMW AβOs can still contribute to fibril formation by serving as a reservoir of Aβ. That is, HMW AβOs may dissociate into smaller LMW AβO that seed fibrillization [128]. This again points to the necessity to track the fate of AβO species when evaluating their physiological activities. For example, the LMW AβOs that are dissociation products of HMW AβOs may actually be more toxic [170].

    Another technique that is capable of characterizing heterogeneous populations of AβOs is ion mobility mass spectrometry (IM-MS). These IM-MS studies ascertained qualitative differences in AβO structure associated with Aβ40 and Aβ42 [131],[132]. Aβ40 tetramers displayed an enclosed ring-shaped configuration that would inhibit additional contacts required to assemble into larger AβO species [131],[132]. Aβ42 tetramers preferentially had a bent structure that would provide oligomer ends capable of additional contacts and enabling further agammaegation. Indeed, Aβ42 was capable of forming larger donut-shaped dodecamers.

    Another strategy to perform structural analysis of AβOs is utilizing specific conditions to stabilize them via a kinetic trap. Such an approach has been successfully used to enable NMR spectroscopy of AβOs [171],[172]. By incubation of Aβ at 4 °C and freeze-trapping with liquid nitrogen, heterogeneous, spherical AβOs were analyzed with 2D NMR and shown to possess in-register parallel β-strand structure similar to fibrils [172]. Based on NMR analysis, Aβ42 pentamers stabilized at a low 4 °C and 10 mM salt concentration were disordered [171]. These Aβ42 pentamers displayed enhanced toxicity compared with protofibrils or fibrils [171]. An atomic model of Aβ42 oligomers consisting of approximately 15–24 peptides has been proposed from a combination of biophysical techniques [173]. These oligomers were prepared by disagammaegation in HFIP followed by resuspension in dilute ammonium hydroxide, preventing fibril formation. These were not end-stage AβOs, as subsequent dilution in PBS resulted in fibril formation. Powder X-ray diffraction patterns of the AβOs were consistent with helical β-sheet pairs wrapped together into a super-helix. This wrapping results in a hole along the super-helix axis, which is consistent with proposed toxic mechanisms in which Aβ forms pathogenic pores. Another proposed structure, based on site-directed spin labeling and electron paramagnetic resonance, shares similarities with this structure [174]. This study used Aβ42 fused to GroES-ubiquitin that formed stable oligomers that were A11 positive. Based on the EPR data, an AβO model was proposed that consisted of a β-sheet with three antiparallel strands with these strands being arranged head to tail. These sheets are further packed face to back as a group of four.

    Even just tracking AβO formation has been challenging. A number of straight forward spectroscopic assays are well-established to track formation and kinetic parameters of fibrils (e.g., ThT), but methods to easily track AβO formation have been lacking. Recently, the use of 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) dyes have been utilized to fluorescently detect the AβOs in vitro [175],[176]. These BODIPY fluorescent probes have high quantum yields with the capability of selectively binding to AβOs [177]. Importantly, increases and decreases in the “BD-Oligo” dye fluorescence also correlated with increasing and decreasing intensities of A11 staining, directly relating this signal to an established methods to detect AβOs [175]. In addition, the BD-Oligo dye can be used in parallel with ThT assays that detect fibril formation, allowing for the direct investigation of the correlation between oligomer and fibril formation [175]. A BODIPY-based probe (BAP-1) has also facilitated the direct visualization of Aβ plaques in transgenic mice [177], and rational modifications of BAP-1 also allowed for near-infrared selective detection of tau neurofibrillary tangles [178]. The ability to rationally modify BODIPY dyes for fluorescent detection of specific agammaegate species, the tunability of their spectroscopic properties, and their insensitivity to solvent and pH changes have made BODIPY dyes a recently promising avenue for high throughput studies of AβO formation and stability.

    While the agammaegation of Aβ has been extensively studied, there is still much to understand at the molecular level about AβO formation, structure, and activity. Due to the transient nature of AβOs, their morphological heterogeneity, and the continuing debate concerning specific toxic agammaegate species associated with AD, structural details and physiological activities of the variety of AβOs still need to be fully elucidated. The exact mechanisms associated of how AβOs lead to cellular dysfunction and death have not fully been explained. Understanding these phenomenon may prove crucial in the effectiveness of therapeutic strategies based on manipulating Aβ production, clearance, and agammaegation. Here, we highlighted some specific features of AβOs and techniques that have provided insight into their structure and formation. While this review is far from exhaustive, we hope that collectively they provide a compelling argument toward the importance of understanding the nature of AβOs, highlight some of the intrinsic obstacles associated with studying AβOs, and provide some insight into methods that will play a role in pushing our knowledge of AβOs further.

    [1] Happé F (2015) Autism as a neurodevelopmental disorder of mind-reading. Abstr Book 3: 197–209.
    [2] Dover CJ, Le Couteur AL (2007) How to diagnose Autism. Arch Dis Child 92: 540–545. doi: 10.1136/adc.2005.086280
    [3] Jukić V, Arbanas G (2013) Diagnostic and Statistical Manual of Mental Disorders; Fifth Edition (DSM-5).Int J 57: 15461548.
    [4] Fombonne E (2009) Epidemiology of pervasive developmental disorders. Pediatr Res 65: 591–598. doi: 10.1203/PDR.0b013e31819e7203
    [5] Fombonne E, Quirke S, Hagen A (2009) Prevalence and interpretation of recent trends in rates of pervasive developmental disorders. McGill J Med 12: 73.
    [6] Weintraub K (2011) Autism counts. Nature 479: 22–24. doi: 10.1038/479022a
    [7] Nazeer A, Ghaziuddin M (2012) Autism spectrum disorders: Clinical features and diagnosis. Pediatr Clin North Am 59: 19–25. doi: 10.1016/j.pcl.2011.10.007
    [8] Zablotsky B, Black LI, Maenner MJ, et al. (2015) Estimated prevalence of autism and other developmental disabilities following questionnaire changes in the 2014 national health interview survey. Natl Health Stat Rep 2015: 1–20.
    [9] Hansen SN, Schendel DE, Parner ET (2015) Explaining the increase in the prevalence of autism spectrum disorders the proportion attributable to changes in reporting practices. JAMA Pediatr 169: 56–62. doi: 10.1001/jamapediatrics.2014.1893
    [10] Mostafa GA, ALayadhi LY (2012) Reduced serum concentrations of 25-hydroxy vitamin D in children with autism: Relation to autoimmunity. J Neuroinflammation 9: 1–7.
    [11] Duan XY, Jia FY, Jiang HY (2013) Relationship between vitamin D and autism spectrum disorder. Chin J Contemp Pediatr 15: 698–702.
    [12] Newschaffer CJ, Croen LA, Daniels J, et al. (2007) The epidemiology of autism spectrum disorders. Annu Rev Public Health 28: 235–258. doi: 10.1146/annurev.publhealth.28.021406.144007
    [13] Christison GW, Ivany K (2006) Elimination diets in autism spectrum disorders: Any wheat amidst the chaff? J Dev Behav Pediatr 27: S162–S171. doi: 10.1097/00004703-200604002-00015
    [14] Meyer U, Feldon J, Dammann O (2011) Schizophrenia and autism: Both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res 69: 26R–33R.
    [15] Wagner CL, Taylor SN, Dawodu A, et al. (2012) Vitamin D and its role during pregnancy in attaining optimal health of mother and fetus. Nutrients 4: 208–230.
    [16] Abdulbari B, Oaa AHA, Saleh NM (2013) Association between vitamin D insufficiency and adverse pregnancy outcome: Global comparisons. Int J Womens Health 5: 523.
    [17] Georgieff MK (2007) Nutrition and the developing brain: Nutrient priorities and measurement. Am J Clin Nutr85: 614S620S.
    [18] Al-Farsi YM, Waly MI, Deth RC, et al. (2013) Impact ofnutrition on serum levels of docosahexaenoic acid among Omani children with autism. Nutrition 29: 11421146.
    [19] Bell JG, Mackinlay EE, Dick JR, et al. (2004) Essential fatty acids and phospholipase A2 in autistic spectrum disorders. Prostaglandins Leukotrienes Essent Fatty Acids 71: 201204.
    [20] Amminger GP, Berger GE, Schafer MR, et al. (2007) Omega-3 fatty acids supplementation in children with autism: A double-blind randomized, placebo-controlled pilot study. Biol Psychol 61: 551553.
    [21] Meguid NA, Atta HM, Gouda AS, et al. (2008) Role of polyunsaturated fatty acids in the management of Egyptian children with autism. Clin Biochem 41: 10441048.
    [22] Meiri G, Bichovsky Y, Belmaker RH (2009) Omega 3 fatty acid treatment in autism. J Child Adolesc Psychopharmacol 19: 449451.
    [23] El-Ansary AK, Ben BAG, Al-Ayahdi LY (2011) Impaired plasma phospholipids and relative amounts of essential polyunsaturated fatty acids in autistic patients from Saudi Arabia. Lipids Health Dis 10: 63. doi: 10.1186/1476-511X-10-63
    [24] Yui K, Koshiba M, Nakamura S, et al. (2012) Effects of large doses of arachi-donic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: A double-blind, placebo-controlled, randomized trial. J Clin Psychopharmacol 32: 200206.
    [25] Gómezpinilla F (2008) Brainfoods: The effect of nutrients on brain function. Nat Rev Neurosci 9: 568578.
    [26] Willis LM, Shukitt-Hale BJ (2009) Recent advances in berry supplementation and age-related cognitive decline. Curr Opin Clin Nutr Metab Care 12: 91–94. doi: 10.1097/MCO.0b013e32831b9c6e
    [27] Gu Y, Nieves JW, Stern Y, et al. (2010) Food combination and Alzheimer disease risk: A protective diet. Arch Neurol 67: 699706.
    [28] Nyaradi A, Li J, Hickling S, et al. (2013) The role of nutrition in children's neurocognitive development, from pregnancy through childhood. Front Hum Neurosci 7: 97.
    [29] Prado EL, Dewey KG (2014) Nutrition and brain development in early life. Nutr Rev 72: 267284.
    [30] Keunen K, Elburg RMV, Bel FV, et al. (2014) Impact of nutrition on brain development and its neuroprotective implications following preterm birth. Pediatr Res 77: 148155.
    [31] Georgieff MK, Rao R, (2001) The role of nutrition in cognitive development. In: Nelson CA, Luciana M, Eds.,Handbook in developmental cognitive neuroscience.Cambridge, MA: MIT Press, 491–504.
    [32] Hultman CM, Sparén P, Cnattingius S (2002) Perinatal risk factors for infantile autism. Epidemiology 13: 417423.
    [33] Dionne G, Boivin M, Seguin JR. et al. (2008) Gestational diabetes hinders language development in offspring. Pediatrics 122: 10731079.
    [34] Leonard H, Klerk N, Bourke J, et al. (2006) Maternal health in pregnancy and intellectual disability in the offspring: A population-based study. Ann Epidemiol 16: 448454.
    [35] Dodds L, Fell DB, Shea S, et al. (2011) The role of prenatal, obsteric and neonatal factors in the development of autism. J Autism Dev Disord 41: 891902.
    [36] Burdge GC, Lillycrop KA (2014) Fatty acids and epigenetics. Curr Opin Clin Nutr Metab Care 17: 156–161. doi: 10.1097/MCO.0000000000000023
    [37] Delong GR (1993) Effects of nutrition on brain development in humans. Am J Clin Nutr 57: S286S290.
    [38] Morgane PJ, Mokler DJ, Galler JR (2002) Effects of prenatal protein malnutrition on the hippocampal formation. Neurosci Biobehav Rev 26: 471–483. doi: 10.1016/S0149-7634(02)00012-X
    [39] Rosales FJ, Reznick JS, Zeisel SH (2009) Understanding the role of nutrition in the brain and behavioral development of toddlers and preschool children: Identifying and addressing methodological barriers. Nutr Neurosci 12: 190–202. doi: 10.1179/147683009X423454
    [40] Mccann JC, Ames BN (2005) Is docosahexaenoic acid, an n-3 long-chain polyunsaturated fatty acid, required for development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals. Am J Clin Nutr 82: 281–295.
    [41] Innis SM (2007) Dietary (n-3) fatty acids and brain development. J Nutr 137: 855–859. doi: 10.1093/jn/137.4.855
    [42] Wu A, Ying Z, Gomezpinilla F (2007) Omega-3 fatty acids supplementation restores mechanisms that maintain brain homeostasis in traumatic brain injury. J Neurotrauma 24: 1587–1595.
    [43] De Souza AS, Fernandes FS (2011) Effects of maternal malnutrition and postnatal nutritional rehabilitation on brain fatty acids, learning, and memory. Nutr Rev 69: 132–144.
    [44] Lozoff B, Georgieff MK (2006) Iron deficiency and brain development. Semin Pediatr Neurol 13: 158–165.
    [45] Zimmermann MB (2011) The role of iodine in human growth and development. Semin Cell Dev Biol 22: 645–652.
    [46] Greenwood CE, Winocur G (2005) High-fat diets, insulin resistance and declining cognitive function. Neurobiol Aging 26: 42–45.
    [47] Molteni R, Barnard RJ, Ying Z, et al. (2002) A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience 112: 803–814.
    [48] Rice D, Barone S (2000) Critical periods of vulnerability for the developing nervous system: Evidence from humans and animal models. Environ Health Perspect 108: 511533.
    [49] Couperus JW,Nelson CA,(2006) Early brain development and plasticity. In: McCartney K, Phillips D, Eds.,The Blackwell Handbook of Early Childhood Development.Malden, MA: Blackwell Publsihing,85105.
    [50] Benton D (2010) The influence of dietary status on the cognitive performance of children. Mol Nutr Food Res 54: 457–470.
    [51] Levitsky DA, Strupp BJ (1995) Malnutrition and the brain: Changing concepts, changing concerns. J Nutr 125: 2212S–2220S. doi: 10.1093/jn/125.suppl_8.2212S
    [52] Penido AB, Rezende GH, Abreu RV, et al. (2012) Malnutrition during central nervous system growth and development impairs permanently the subcortical auditory pathway. Nutr Neurosci 15: 31–36. doi: 10.1179/1476830511Y.0000000022
    [53] Roseboom TJ, Painter RC, Van Abeelen AF, et al. (2011) Hungry in the womb: What are the consequences? Lessons from the Dutch famine. Maturitas 70: 141–145.
    [54] Kerac M, Postels DG, Mallewa M, et al. (2014) The interaction of malnutrition and neurologic disability in Africa. Semin Pediatr Neurol 21: 42–49. doi: 10.1016/j.spen.2014.01.003
    [55] Jacka FN, Pasco JA, Mykletun A, et al. (2010) Association of western and traditional diets with depression and anxiety in women. Am J Psychiatry 167: 305–311. doi: 10.1176/appi.ajp.2009.09060881
    [56] Jacka FN, Pasco JA, Mykletun A, et al. (2011) Diet quality in bipolar disorder in a population-based sample of women. J Affective Disord 129: 332–337. doi: 10.1016/j.jad.2010.09.004
    [57] Forsyth AK, Williams PG, Deane FP (2011) Nutrition status of primary care patients with depression and anxiety. Aust J Primary Health 18: 172–176.
    [58] Scarmeas N, Stern Y, Tang MX, et al. (2006) Mediterranean diet and risk for Alzheimer's disease. Ann Neurol 59: 912–921. doi: 10.1002/ana.20854
    [59] Francesco S, Francesca C, Rosanna A, et al. (2008) Adherence to Mediterranean diet and health status: A meta-analysis. BMJ 337: a1344. doi: 10.1136/bmj.a1344
    [60] Scarmeas N, Stern Y, Mayeux R, et al. (2009) Mediterranean diet and mild cognitive impairment. Arch Neurol 66: 216–225.
    [61] Eilander A, Gera T, Sachdev HS, et al. (2010) Multiple micronutrient supplementation for improving cognitive performance in children: Systematic review of randomised controlled trials. Am J Clin Nutr 91: 115–130. doi: 10.3945/ajcn.2009.28376
    [62] Schoenthaler SJ, Amos S, Doraz W, et al. (1997) The effect of randomized vitamin-mineral supplementation on violent and non-violent antisocial behavior among incarcerated juveniles. J Nutr Environ Med 7: 343–352. doi: 10.1080/13590849762475
    [63] Schoenthaler SJ, Bier ID (1999) Vitamin-mineral intake and intelligence: A macrolevel analysis of randomised controlled trials. J Altern Complementary Med 5: 125–134. doi: 10.1089/acm.1999.5.125
    [64] Zaalberg A, Nijman H, Bulten E, et al. (2010) Effects of nutritional supplements on aggression, rule-breaking, and psychopathology among young adult prisoners. Aggressive Behav 36: 117–126. doi: 10.1002/ab.20335
    [65] Buffington SA, Di PG, Auchtung TA, et al. (2016) Microbial reconstitution reverses maternal diet-induced social and synaptic deficits in offspring. Cell 165: 1762–1775. doi: 10.1016/j.cell.2016.06.001
    [66] Bazinet RP, Layé S (2014) Polyunsaturated fatty acids and their metabolites in brain function and disease. Nat Rev Neurosci 15: 771–785. doi: 10.1038/nrn3820
    [67] Innis S, De-La-Presa-Owens S (2001) Dietary fatty acid composition in pregnancy alters neurite membrane fatty acids and dopamine in newborn rat brain. J Nutr 131: 118–122. doi: 10.1093/jn/131.1.118
    [68] Pardo CA, Eberhart CG (2007) The neurobiology of autism. Brain Pathol 17: 434–447. doi: 10.1111/j.1750-3639.2007.00102.x
    [69] Chalon S (2006) Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukotrienes Essent Fatty Acids 75: 259–269. doi: 10.1016/j.plefa.2006.07.005
    [70] Zimmer L, Delpal S, Guilloteau D, et al. (2000) Chronic n-3 polyunsaturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neurosci Lett 284: 25–28. doi: 10.1016/S0304-3940(00)00950-2
    [71] Aïd S, Vancassel S, Poumès-Ballihaut C, et al. (2003) Effect of a diet-induced n-3 PUFA depletion on cholinergic parameters in the rat hippocampus. J Lipid Res 44: 1545–1551. doi: 10.1194/jlr.M300079-JLR200
    [72] Takeuchi T, Iwanaga M, Harada E (2003) Possible regulatory mechanism of DHA-induced anti-stress reaction in rats. Brain Res 964: 136–143. doi: 10.1016/S0006-8993(02)04113-6
    [73] Fedorova I, Alvheim AR, Hussein N, et al. (2009) Deficit in prepulse inhibition in mice caused by dietary n-3 fatty acid deficiency. Behav Neurosci 123: 1218–1225. doi: 10.1037/a0017446
    [74] Larrieu T, Hilal LM, Fourrier C, et al. (2014) Nutritional omega-3 modulates neuronal morphology in the prefrontal cortex along with depression-related behaviour through corticosterone secretion. Transl Psychiatry 4: e437. doi: 10.1038/tp.2014.77
    [75] Larrieu T, Madore C, Joffre C, et al. (2012) Nutritional n-3 polyunsaturated fatty acids deficiency alters cannabinoid receptor signalling pathway in the brain and associated anxiety-like behavior in mice. J Physiol Biochem 68: 671–681. doi: 10.1007/s13105-012-0179-6
    [76] Jones ML, Mark PJ, Waddell BJ (2013) Maternal omega-3 fatty acid intake increases placental labyrinthine antioxidant capacity but does not protect against fetal growth restriction induced by placental ischaemia-reperfusion injury. Reproduction 146: 539–547. doi: 10.1530/REP-13-0282
    [77] Li Q, Leung YO, Zhou I, et al. (2015) Dietary supplementation with n-3 fatty acids from weaning limits brain biochemistry and behavioural changes elicited by prenatal exposure to maternal inflammation in the mouse model. Transl Psychiatry 5: e641. doi: 10.1038/tp.2015.126
    [78] Labrousse VF, Nadjar A, Joffre C, et al. (2012) Short-term long chain Omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice. PLoS One 7: e36861. doi: 10.1371/journal.pone.0036861
    [79] Kerr M (2008) Neurodevelopmental delays associated with iron-fortified formula for healthy infants. Med Psychiatry Mental Health.
    [80] Stein Z, Susser M, Saenger G, et al. (1975) Famine and human development: The Dutch hunger winter of 1944–1945. Q Rev Biol 7: 1944–1945.
    [81] Hoek HW, Susser E, Buck KA, et al. (1996) Schizoid personality disorder after prenatal exposure to famine. Am J Psychiatry 153: 1637–1639. doi: 10.1176/ajp.153.12.1637
    [82] Susser E, Neugebauer R, Hoek HW, et al. (1996) Schizophrenia after prenatal famine: Further evidence. Arch Gen Psychiatry 53: 25–31. doi: 10.1001/archpsyc.1996.01830010027005
    [83] Susser E, Hoek HW, Brown A (1998) Neurodevelopmental Disorders after Prenatal Famine: The Story of the Dutch Famine Study. Am J Epidemiol 147: 214–216.
    [84] Millichap JG, Yee MM (2012) The Diet Factor in Attention-Deficit/hyperactivity disorder. Paediatrics 129: 330. doi: 10.1542/peds.2011-2199
    [85] Surén P, Roth C, Bresnahan M, et al. (2013) Association between maternal use of folic acid supplements and risk of autism spectrum disorders in children. J Am Med Assoc 309: 570–577. doi: 10.1001/jama.2012.155925
    [86] Grant WB, Soles CM (2009) Epidemiologic evidence supporting the role of maternal vitamin D deficiency as a risk factor for the development of infantile autism. Dermatoendocrinology 1: 223–228. doi: 10.4161/derm.1.4.9500
    [87] Blaylock RL (2009) Possible central mechanism in autism spectrum disorders, part 3: The role of excitotoxin food additives and the synergistic effects of other environmental toxins. Altern Ther Health Med 15: 56–60.
    [88] Macfabe DF, Cain DP, Rodriguez-Capote K, et al. (2007) Neurobiological effects of intraventricular propionic acid in rats: Possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders.Behav Brain Res176: 149169.
    [89] Macfabe DF, Cain NE, Boon F, et al. (2011) Effects of the enteric bacterial metabolic product propionic acid on object-directed behavior, social behavior, cognition, and neuroinflammation in adolescent rats: Relevance to autism spectrum disorder. Behav Brain Res 217: 47–54. doi: 10.1016/j.bbr.2010.10.005
    [90] El-Ansary AK, Bacha AB, Kotb M (2012) Etiology of autistic features: The persisting neurotoxic effects of propionic acid. J Neuroinflammation 9: 74.
    [91] Bourgeron T (2007) The possible interplay of synaptic and clock genes in autism spectrum disorders. Cold Spring Harb Symp Quant Biol 72: 645–654. doi: 10.1101/sqb.2007.72.020
    [92] Bourgeron T (2009) A synaptic trek to autism. Curr Opin Neurobiol 19: 231–234. doi: 10.1016/j.conb.2009.06.003
    [93] Bourgeron T (2015) From the genetic architecture to synaptic plasticity in autism spectrum disorder. Nat Rev Neurosci 16: 551–563. doi: 10.1038/nrn3992
    [94] Oberman LM, Ifertmiller F, Najib U, et al. (2016) Abnormal echanisms of plasticity and metaplasticity in autism spectrum disorders and fragile X syndrome. J Child Adolesc Psychopharmacol 26: 617–624. doi: 10.1089/cap.2015.0166
    [95] Georgieff MK, Brunette KE, Tran PV (2015) Early life nutrition and neural plasticity. Dev Psychopathol 27: 411–423. doi: 10.1017/S0954579415000061
    [96] Madore C, Nadjar A, Delpech JC, et al. (2014) Nutritional n-3 PUFAs deficiency during perinatal periods alters brain innate immune system and neuronal plasticity-associated genes. Brain Behav Immun 41: 22–31. doi: 10.1016/j.bbi.2014.03.021
    [97] Lafourcade M, Larrieu T, Mato S, et al. (2011) Nutritional omega-3 deficiency abolishes endocannabinoid-mediated neuronal functions. Nat Neurosci 14: 345–350. doi: 10.1038/nn.2736
    [98] Thomazeau A, Boschbouju C, Manzoni O, et al. (2016) Nutritional n-3 PUFA deficiency abolishes endocannabinoid gating of hippocampal long-term potentiation. Cereb Cortex 27: 2571–2579.
    [99] Fatemi SH, Aldinger KA, Ashwood P, et al. (2012) Consensus paper: Pathological role of the cerebellum in autism. Cerebellum 11: 777–807. doi: 10.1007/s12311-012-0355-9
    [100] Harada M, Taki MM, Nose A, et al. (2011) Non-invasive evaluation of the gabaergic/glutamatergic system in autistic patients observed by mega-editing proton MR spectroscopy using a clinical 3 tesla instrument. J Autism Dev Disord 41: 447–454. doi: 10.1007/s10803-010-1065-0
    [101] Blatt GJ, Fatemi SH (2011) Alterations in gabaergic biomarkers in the autism brain: Research findings and clinical implications. Anat Rec 294: 1646–1652. doi: 10.1002/ar.21252
    [102] Hogart A, Leung KN, Wang NJ, et al. (2009) Chromosome 15q11-13 duplication syndrome brain reveals epigenetic alterations in gene expression not predicted from copy number. J Med Genet 46: 86–93.
    [103] Xu LM, Li JR, Huang Y, et al. (2012) Autismkb: An evidence-based knowledgebase of autism genetics. Nucleic Acids Res 40: 1016–1022. doi: 10.1093/nar/gkr1145
    [104] Jamain S, Betancur C, Quach H, et al. (2002) Linkage and association of the glutamate receptor 6 gene with autism. Mol Psychiatry 7: 302–310. doi: 10.1038/sj.mp.4000979
    [105] Yang Y, Pan C (2013) Role of metabotropic glutamate receptor 7 in autism spectrum disorders: A pilot study. Life Sci 92: 149–153. doi: 10.1016/j.lfs.2012.11.010
    [106] Yip J, Soghomonian JJ, Blatt GJ (2007) Decreased GAD67 mrna levels in cerebellar purkinje cells in autism: Pathophysiological implications. Acta Neuropathol 113: 559–568. doi: 10.1007/s00401-006-0176-3
    [107] Aldred S, Moore KM, Fitzgerald M, et al. (2003) Plasma amino acid levels in children with autism and their families. J Autism Dev Disord 33: 93–97. doi: 10.1023/A:1022238706604
    [108] Shinohe A, Hashimoto K, Nakamura K, et al. (2006) Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacology Biol Psychiatry 30: 1472–1477. doi: 10.1016/j.pnpbp.2006.06.013
    [109] Sutcliffe JS, Delahanty RJ, Prasad HC, et al. (2005) Allelic heterogeneity at the serotonin transporter locus (slc6a4) confers susceptibility to autism and rigid-compulsive behaviors. Am J Hum Genet 77: 265–279.
    [110] Levitt P (2011) Serotonin and the autisms: A red flag or a red herring? Arch Gen Psychiatry 68: 1093–1094. doi: 10.1001/archgenpsychiatry.2011.98
    [111] Muller CL, Anacker AM, Veenstravanderweele J (2016) The serotonin system in autism spectrum disorder: From biomarker to animal models. Neuroscience 321: 24–41. doi: 10.1016/j.neuroscience.2015.11.010
    [112] Mccracken JT, Mcgough J, Shah B, et al. (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347: 314–321. doi: 10.1056/NEJMoa013171
    [113] Pavăl D (2017) A Dopamine Hypothesis of Autism Spectrum Disorder. Dev Neurosci 39: 355–360. doi: 10.1159/000478725
    [114] Nakamura K, Sekine Y, Ouchi Y, et al. (2010) Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry 67: 59–68. doi: 10.1001/archgenpsychiatry.2009.137
    [115] Kałuzna-Czaplińska J, Socha E, Rynkowski J (2010) Determination of homovanillic acid and vanillylmandelic acid in urine of autistic children by gas chromatography/mass spectrometry. Med Sci Monit 16: CR445–CR450.
    [116] Anderson GH, Johnston JL (1983) Nutrient control of brain neurotransmitter synthesis and function. Can J Physiol Pharmacol 61: 271–281. doi: 10.1139/y83-042
    [117] Fernstrom JD, Fernstrom MH (2007) Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr 137: 1539S–1547S. doi: 10.1093/jn/137.6.1539S
    [118] Schmidt RJ, Tancredi DJ, Krakowiak P, et al. (2014) Maternal intake of supplemental iron and risk of autism spectrum disorder. Am J Epidemiol 180: 890–900. doi: 10.1093/aje/kwu208
    [119] Eyles DW, Burne TH, Mcgrath JJ (2013) Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. Front Neuroendocrinol 34: 47–64. doi: 10.1016/j.yfrne.2012.07.001
    [120] Whitehouse AJ, Holt BJ, Serralha M, et al. (2013) Maternal vitamin D levels and the autism phenotype among offspring. J Autism Dev Disord 43: 1495. doi: 10.1007/s10803-012-1676-8
    [121] Tylavsky FA, Kocak M, Murphy LE, et al. (2015) Gestational vitamin 25(OH)D status as a risk factor for receptive language development: A 24-month, longitudinal, observational study. Nutrients 7: 9918–9930. doi: 10.3390/nu7125499
    [122] Morales E, Guxens M, Llop S, et al. (2012) Circulating 25-hydroxyvitamin D3 in pregnancy and infant neuropsychological development. Pediatrics 130: e913–e920. doi: 10.1542/peds.2011-3289
    [123] Keim SA, Bodnar LM, Klebanoff MA (2014) Maternal and cord blood 25(OH)-vitamin D concentrations in relation to child development and behaviour. Paediatr Perinat Epidemiol 28: 434–444. doi: 10.1111/ppe.12135
    [124] Magnusson C, Rai D, Goodman A, et al. (2012) Migration and autism spectrum disorder: Population-based study. Br J Psychiatry 201: 109–115. doi: 10.1192/bjp.bp.111.095125
    [125] Holick MF (2007) Vitamin D deficiency. N Engl J Med 357: 266–281. doi: 10.1056/NEJMra070553
    [126] Vinkhuyzen AA, Eyles DW, Burne TH, et al. (2016) Gestational vitamin D deficiency and autism-related traits: The Generation R Study. Mol Psychiatry 23: 240246.
    [127] Liu X, Liu J, Xiong X, et al. (2016) Correlation between Nutrition and Symptoms: Nutritional Survey of Children with Autism Spectrum Disorder in Chongqing, China. Nutrients 8: 294. doi: 10.3390/nu8050294
    [128] Egan AM, Dreyer ML, Odar CC, et al. (2013) Obesity in young children with autism spectrum disorders: Prevalence and associated factors. Child Obes 9: 125–131. doi: 10.1089/chi.2012.0028
    [129] Adams JB, Vogelaar AT, (2005) Nutritional abnormalities in autism and effects of nutritional supplementation, In: ASA's 36th National Conference on Autism Spectrum Disorders, Nashville, TN.
    [130] Strambi M, Longini M, Hayek J, et al. (2006) Magnesium profile in autism. Biol Trace Elem Res 109: 97–104. doi: 10.1385/BTER:109:2:097
    [131] Pineless SL, Avery RA, Liu GT (2010) Vitamin B12 optic neuropathy in autism. Pediatrics 126: e967–e970. doi: 10.1542/peds.2009-2975
    [132] Gong ZL, Luo CM, Wang L, et al. (2014) Serum 25-hydroxyvitamin D levels in Chinese children with autism spectrum disorders. Neuroreport 25: 23–27.
    [133] Kocovska E, Andorsdottir G, Weihe P, et al. (2014) Vitamin d in the general population of young adults with autism in the faroe islands. J Autism Dev Disord 44: 2996–3005. doi: 10.1007/s10803-014-2155-1
    [134] Filipek PA, Juranek J, Nguyen MT, et al. (2004) Relative carnitine deficiency in autism. J Autism Dev Disord 34: 615–623. doi: 10.1007/s10803-004-5283-1
    [135] Adams JB (2013) Summary of Dietary, Nutritional, and Medical Treatments for Autism-based on over 150 published research studies. Autism Reasearch Institute Publication 40-Version. Available from: http://autism.asu.edu.
    [136] Berry RC, Novak P, Withrow N, et al. (2015) Nutrition Management of Gastrointestinal Symptoms in Children with Autism Spectrum Disorder: Guideline from an Expert Panel. J Acad Nutr Diet 115: 1919–1927. doi: 10.1016/j.jand.2015.05.016
    [137] Stewart PA, Hyman SL, Schmidt BL, et al. (2015) Dietary Supplementation in Children with Autism Spectrum Disorders: Common, Insufficient, and Excessive. J Acad Nutr Diet 115: 1237–1248. doi: 10.1016/j.jand.2015.03.026
    [138] Santosh PJ, Singh J (2016) Drug treatment of autism spectrum disorder and its comorbidities in children and adolescents. BJ Psych Adv 22: 151–161.
    [139] Brondino N, Fusar-Poli L, Panisi C, et al. (2016) Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies. J Autism Dev Disord 46: 825–839. doi: 10.1007/s10803-015-2619-y
    [140] Kumar B, Prakash A, Sewal RK, et al. (2012) Drug therapy in autism: A present and future perspective. Pharmacol Rep 64: 1291–1304. doi: 10.1016/S1734-1140(12)70927-1
    [141] Doyle CA, Mcdougle CJ (2012) Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci 14: 263–279.
    [142] Croen LA, Grether JK, Yoshida CK, et al. (2011) Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 68: 1104–1112. doi: 10.1001/archgenpsychiatry.2011.73
    [143] Aman MG, Arnold LE, Mcdougle CJ, et al. (2005) Acute and long-term safety and tolerability of risperidone in children with autism. J Child Adolesc Psychopharmacol 15: 869–884. doi: 10.1089/cap.2005.15.869
    [144] Mcdougle CJ, Scahill L, Aman MG, et al. (2005) Risperidone for the core symptom domains of autism: Results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 16: 1142–1148.
    [145] Buitelaar JK, Willemsen-Swinkels SHN (2000) Medication treatment in subjects with autistic spectrum disorders. Eur Child Adolesc Psychiatry 9: S85–S97. doi: 10.1007/s007870070022
    [146] Aoki Y, Yahata N, Watanabe T, et al. (2014) Oxytocin improves behavioural and neural deficits in inferring others' social emotions in autism. Brain 137: 3073–3086. doi: 10.1093/brain/awu231
    [147] Watanabe T, Abe O, Kuwabara H, et al. (2014) Mitigation of sociocommunicational deficits of autism through oxytocin-induced recovery of medial prefrontal activity: A randomized trial. JAMA Psychiatry 71: 166–175. doi: 10.1001/jamapsychiatry.2013.3181
    [148] Geraghty ME, Bates-Wall J, Ratliff-Schaub K, et al. (2010) Nutritional interventions and therapies in autism: A spectrum of what we know: Part 2. Ican Infant Child Adolesc Nutr 2: 120–133.
    [149] Geraghty ME, Depasquale GM, Lane AE (2010) Nutritional intake and therapies in autism: A spectrum of what we know: Part 1. Ican Infant Child Adolesc Nutr 2: 62–69. doi: 10.1177/1941406409358437
    [150] Marti LF (2014) Dietary interventions in children with autism spectrum disorders-an updated review of the research evidence. Curr Clin Pharmacol 9: 335–349. doi: 10.2174/15748847113086660074
    [151] Kawicka A, Regulska-Ilow B (2013) How nutrition status, diet and dietary supplements can affect autism. A review. Rocz Panstw Zakl Hig 64: 1–12.
    [152] Curtis LT, Patel K (2008) Nutritional and environmental approaches to preventing and treating autism and attention deficit hyperactivity disorder (ADHD): A review. J Altern Complement Med 14: 79–85. doi: 10.1089/acm.2007.0610
    [153] Kidd PM (2002) Autism, an extreme challenge to integrative medicine. Part II: Medical Management. Altern Med Rev 7: 472–499.
    [154] Kidd PM (2002) Autism, an extreme challenge to integrative medicine. Part 1: The knowledge base. Altern Med Rev 7: 292316.
    [155] Pilla SSDD, Ravisankar P, Penugonda V, et al. (2014) Dietary interventions in Autism Spectrum Disorders. AP J Psychol Med 15: 24–31.
    [156] Joanna KCE, Rynkowski JB (2011) Vitamin supplementation reduces excretion of urinary dicarboxylic acids in autistic children. Nutr Res 31: 497–502. doi: 10.1016/j.nutres.2011.06.002
    [157] Mousainbosc M, Roche M, Polge A, et al. (2006) Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. II. Pervasive developmental disorder-autism. Magnesium Res 19: 53–62.
    [158] Adams JB, Holloway C (2004) Pilot study of a moderate dose multivitamin/mineral supplement for children with autistic spectrum disorder. J Altern Complement Med 10: 1033–1039. doi: 10.1089/acm.2004.10.1033
    [159] Adams JB, Audhya T, Mcdonoughmeans S, et al. (2011) Effect of a vitamin/mineral supplement on children and adults with autism. BMC Pediatr 11: 111. doi: 10.1186/1471-2431-11-111
    [160] Cannell JJ (2008) Autism and vitamin D. Med Hypotheses 70: 750–759. doi: 10.1016/j.mehy.2007.08.016
    [161] Jia F, Wang B, Shan L, et al. (2015) Core symptoms of autism improved after vitamin D supplementation. Pediatrics 135: e196–e198. doi: 10.1542/peds.2014-2121
    [162] Saad K, Abdel-Rahman AA, Elserogy YM, et al. (2018) Randomized controlled trial of vitamin D supplementation in children with autism spectrum disorder. J Child Psychol Psychiatry 59: 20–29. doi: 10.1111/jcpp.12652
    [163] Jia F, Shan L, Wang B, et al. (2017) Bench to bedside review: Possible role of vitamin D in autism spectrum disorder. Psychiatry Res 260: 360–365.
    [164] Politi P, Cena H, Emanuele E (2011) Dietary Supplementation of Omega-3 Polyunsaturated Fatty Acids in Autism. Handb Behav Food Nutr 88: 1787–1796.
    [165] Malow BA, Adkins KW, Mcgrew SG, et al. (2012) Melatonin for sleep in children with autism: A controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord 42: 1729–1737. doi: 10.1007/s10803-011-1418-3
    [166] Reading R (2011) Melatonin in autism spectrum disorders: A systematic review and meta-analysis. Dev Med Child Neurol 53: 783–792. doi: 10.1111/j.1469-8749.2011.03980.x
    [167] Critchfield JW, Van HS, Ash M, et al. (2011) The potential role of probiotics in the management of childhood autism spectrum disorders. Gastroenterol Res Pract 2011: 161358.
    [168] Hsiao EY, Mcbride SW, Hsien S, et al. (2013) The microbiota modulates gut physiology and behavioral abnormalities associated with autism. Cell 155: 1451–1463. doi: 10.1016/j.cell.2013.11.024
    [169] Shaaban SY, El Gendy YG, Mehanna NS, et al. (2017) The role of probiotics in children with autism spectrum disorder: A prospective, open-label study. Nutr Neurosci 2017: 1–6.
    [170] Gvozdjáková A, Kucharská J, Ostatníková D, et al. (2014) Ubiquinol improves symptoms in children with autism. Oxid Med Cell Longevity 2014: 798957.
    [171] Geier DA, Kern JK, Davis G, et al. (2011) A prospective double-blind, randomized clinical trial of levocarnitine to treat autism spectrum disorders. Med Sci Monit 17: P115–P123.
    [172] Hardan AY, Fung LK, Libove RA, et al. (2012) A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry 71: 956–961. doi: 10.1016/j.biopsych.2012.01.014
    [173] Chez MG, Buchanan CP, Aimonovitch MC, et al. (2002) Double-blind, placebo-controlled study of L-carnosine supplementation in children with autistic spectrum disorders. J Child Neurol 17: 833–837. doi: 10.1177/08830738020170111501
    [174] Elder JH (2008) The gluten-free, casein-free diet in autism: An overview with clinical implications. Nutr Clin Pract 23: 583–588. doi: 10.1177/0884533608326061
    [175] Mulloy TA, Lang R, Reilly OM, et al. (2009) Gluten-free and casein-free diets in the treatment of autism spectrum disorders: A systematic review. Res Autism Spectrum Disord 4: 328–339.
    [176] Cade R, Privette M, Fregly M, et al. (2000) Autism and Schizophrenia: Intestinal disorders. Nutr Neurosci 3: 57–72. doi: 10.1080/1028415X.2000.11747303
    [177] Whiteley P, Haracopos D, Knivsberg AN, et al. (2010) The ScanBrit randomized, controlled, single-blind study of a gluten- and casein- free dietary intervention for children with autism spectrum disorders. Nutr Neurosci 13: 87–100. doi: 10.1179/147683010X12611460763922
    [178] Evangeliou A, Vlachonikolis I, Mihailidou H, et al. (2003) Application of a ketogenic diet in children with autistic behavior: Pilot study. J Child Neurol 18: 113–118. doi: 10.1177/08830738030180020501
    [179] Rossignol DA (2009) Novel and emerging treatments for autism spectrum disorders: A systematic review. Ann Clin Psychiatry 21: 213–236.
    [180] Elrashidy O, Elbaz F, Elgendy Y, et al. (2017) Ketogenic diet versus gluten free casein free diet in autistic children: A case-control study. Metab Brain Dis 32: 1935–1941. doi: 10.1007/s11011-017-0088-z
    [181] Strickland E (2009) Eating for Autism: The 10-step Nutrition Plan to Treat Your Child's Autism, Asperger's, or ADHD. Philadelphia, PA: Da Capo Press.
  • This article has been cited by:

    1. Albert W. Pilkington, Gregory C. Donohoe, Novruz G. Akhmedov, Timothy Ferrebee, Stephen J. Valentine, Justin Legleiter, Hydrogen Peroxide Modifies Aβ–Membrane Interactions with Implications for Aβ40 Aggregation, 2019, 58, 0006-2960, 2893, 10.1021/acs.biochem.9b00233
    2. Albert W. Pilkington, Jane Schupp, Morgan Nyman, Stephen J. Valentine, David M. Smith, Justin Legleiter, Acetylation of Aβ40 Alters Aggregation in the Presence and Absence of Lipid Membranes, 2020, 11, 1948-7193, 146, 10.1021/acschemneuro.9b00483
    3. Kristine L. Teppang, Qilin Zhao, Jerry Yang, Development of fluorophores for the detection of oligomeric aggregates of amyloidogenic proteins found in neurodegenerative diseases, 2023, 11, 2296-2646, 10.3389/fchem.2023.1343118
    4. Akane Iida-Adachi, Hideki Nabika, Changes in Adsorption, Aggregation, and Diffusion Nature of Amyloid β on a Lipid Membrane in an Open System, 2025, 0743-7463, 10.1021/acs.langmuir.4c03663
    5. Anjola Adewoye, Ephraim Ezeigbo, Quan H. Vo, Justin Legleiter, Amyloidogenic SARS-CoV-2 Spike Protein-Derived Peptides Form Oligomers and Selectively Damage Lipid Membranes, 2025, 0006-2960, 10.1021/acs.biochem.5c00290
  • Reader Comments
  • © 2018 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(12708) PDF downloads(2160) Cited by(9)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog